GlassScriptPhysician profile
Charles A Rhodes
NPI 1437105855
$3,355.46
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $264 · 2021: $565 · 2022: $721 · 2023: $741 · 2024: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,058.54 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.36 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $282.45 | 2021-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $247.13 | 2019-2024 | |
| Abbott Laboratories | $240.83 | 2022-2023 | Cardiomems |
| Janssen Pharmaceuticals, INC | $170.17 | 2020-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.37 | 2019-2024 | Lifevest |
| Acist Medical Systems, INC. | $150.00 | 2022 | |
| Amgen INC. | $120.10 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $119.15 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $108.08 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $64.32 | 2022 | |
| Amarin Pharma, INC. | $55.42 | 2019 | |
| Esperion Therapeutics, INC. | $52.02 | 2020-2021 | |
| Medtronic USA, INC. | $50.39 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.89 | 2023 | |
| Tactile Systems Technology INC | $28.72 | 2020-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $24.24 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $24.19 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $18.60 | 2023 | Arcalyst |
| Medtronic, INC. | $17.59 | 2024 | Venaseal |
| Bayer Healthcare Pharmaceuticals INC. | $15.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.